

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 15, 2024; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board of directors (the “**Board**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) is pleased to announce the poll results of the extraordinary general meeting of the Company (the “**EGM**”) held at 10:00 a.m. on January 15, 2024 at Meeting Room 1, R&D Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the People’s Republic of China.

References are made to the notice of the EGM and circular of the Company dated December 22, 2023 (the “**Circular**”). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

Shareholders (or their proxies) attending the EGM held 193,689,795 Shares with voting rights in aggregate, representing approximately 88.36% of the total issued Shares of the Company.

Poll Results of Resolutions Proposed at the EGM

Resolutions of the EGM were voted on by poll. The voting results of the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTION		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the appointment of KPMG as the auditors of the Company for the year 2023 to hold office until the conclusion of the next annual general meeting of the Company and to authorize the board of directors of the Company to determine their remuneration.	193,679,613 (99.99%)	0 (0.00%)	10,182 (0.01%)

SPECIAL RESOLUTION		Number of Votes (%)		
		For	Against	Abstain
2.	To consider and approve the proposed amendments to the articles of association of the Company set out in the circular of the Company dated December 22, 2023.	193,689,795 (100.00%)	0 (0.00%)	0 (0.00%)

Notes:

- (a) As more than one-half of the votes were cast in favour of resolution 1 of the EGM, the said resolution was duly passed as an ordinary resolution of the Company.
- (b) As above two-thirds of the votes were cast in favour of resolution 2 of the EGM, the said resolution was duly passed as a special resolution of the Company.
- (c) As at the date of the EGM, the total number of issued Shares of the Company was 219,195,499 Shares, consisting of 87,157,052 domestic shares, 5,414,042 unlisted foreign shares and 126,624,405 H shares of the Company.
- (d) The total number of Shares of the Company entitling the holders to attend and vote on the resolutions at the EGM was 219,195,499 Shares, consisting of 87,157,052 domestic shares, 5,414,042 unlisted foreign shares and 126,624,405 H shares of the Company.
- (e) None of the Shares of the Company entitling the holders to attend the EGM required the holders to abstain from voting in favour of the resolutions pursuant to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (f) None of the Shareholders of the Company was required to abstain from voting on the resolutions at the EGM under the Listing Rules.
- (g) None of the Shareholders of the Company have stated their intention in the Circular to vote against or abstain from voting on any of the resolutions at the EGM.
- (h) The convening of and the procedure for the holding of the EGM was in compliance with the requirements of PRC laws, administrative regulations and the Articles of Association.
- (i) The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, two representatives of the Shareholders and a representative of the Supervisors acted as the counters and scrutineers for the vote-taking at the EGM.
- (j) The following Directors of the Company attended the EGM either in person or through video or teleconference: Mr. LIU Gexin, chairman of the Board and non-executive Director; Dr. GE Junyou, executive Director; Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang, non-executive Directors; and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong, independent non-executive Directors. Dr. WANG Jingyi, executive Director, was unable to attend the EGM due to other business commitments.

Amendments to the Articles of Association

A special resolution was passed by the Shareholders at the EGM to approve the proposed amendments to the Articles of Association as set out in the Circular. Accordingly, the amended Articles of Association shall become effective from the date of the EGM. The full text of the amended Articles of Association will be published on the websites of the Company (<http://kelun-biotech.com>) and the Stock Exchange (www.hkexnews.hk).

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, January 15, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.